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PBSCT may be an attractive treatment option for patients with
POEMS syndrome. Methods: Between March 1999 and February
2003, 11 patients with POEMS syndrome underwent PBSCT at
Mayo Clinic Rochester and Jacksonville. Conditioning regimens
were single agent melphalan (n  9) and BEAM (n  1). All
received a minimum of 4.4  106 CD34 autologous PBSC/kg.
Standard supportive care with prophylactic antibiotics and growth
factor support was provided. Results: All but one had a severe
rapidly progressive sensorimotor PN involving both upper and
lower extremities, 7 wheelchair conﬁned. One patient had sensory
neuropathy without signiﬁcant motor involvement. All but one was
male. A monoclonal lambda PCD was documented in all patients,
and two had biopsy proven Castleman Disease. Median age was 50
years (range 19-62). Seven had organomegaly (5 splenomegaly; 2
hepatomegaly; and 3 lymphadenopathy). Both endocrinopathy and
skin changes were present in 9 patients. Seven had thrombocytosis
and/or erythrocytosis, and 8 had sclerotic bone lesions (diffuse in 5,
solitary lesion in 3). Using the Bardwick Criteria, the median
number of POEMS features was 5 (range 2-5). The median num-
ber of therapeutic regimens prior to PBSCT was 3 (range 0-6).
From ﬁrst symptoms and from diagnosis of POEMS the median
times to transplant were 27 and 10 months (ranges 4-180 and
2-180), respectively. All but one patient had signiﬁcantly abnormal
pre-transplant pulmonary function tests. Of the 8 evaluable pa-
tients, all have had a hematologic response and 7 have had neuro-
logic improvement at a median follow-up of 6 months. Other
symptoms including fatigue, organomegaly, pulmonary compro-
mise, hyperpigmentation and extravascular volume overload have
improved substantially in affected patients. Since February 2003,
an additional 4 patients have been transplanted, but are not yet
evaluable. Conclusions: PBSCT for POEMS syndrome may re-
sult in a high hematologic response rate and improvement in
peripheral neuropathy and systemic symptoms. The outcome of
these patients will be updated at the meeting.
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GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE AFTER AUTOLO-
GOUS STEM CELL TRANSPLANT: INCIDENCE, OUTCOME, AND RISK
FACTORS
Holmberg, L.A.1,2, Gooley, T.1,2, Kikuchi, K.1, Adams, K.M.1,2, Schoch,
G.H.1,2, Bensinger, W.I.1,2, McDonald, G.B.1,2 1. Fred Hutchinson
Cancer Research Center, Seattle, WA; 2. University of Washington,
Seattle, WA
GVHD has been described in the skin, intestinal mucosa, and
liver after autologous stem cell transplantation. The mechanisms
and risk factors for non-cyclosporine-induced autologous GVHD
are unknown. Methods: We reviewed 681 consecutive autologous
transplant patients treated between 1995–1999 to determine the
incidence of response to treatment, and risk factors for developing
gastrointestinal GVHD. GVHD was deﬁned by persistent symp-
toms, mucosal abnormalities at endoscopy, histology showing ap-
optotic crypt-cells and lymphoid inﬁltrates, and absence of infec-
tion. Results: The incidence of GVHD was 90/681 (13%), with
nausea, vomiting, and anorexia in 90% and diarrhea in 37%. The
mean time to onset was day  15 and endoscopic diagnosis day 
45. Treatment with prednisone (1 mg/kg/d) for 10-14 days fol-
lowed by a taper effected durable responses in 72%; an additional
19% responded to a second course. GVHD developed in 18% of
the women and 8% of the men. Signiﬁcant risk factors in univariate
analysis included female sex (p  .0009), diagnosis of breast cancer
(BRCA) (p  .0001), IL-2 therapy (p  .04), Busulfan/Melphalan/
Thiotepa (BUMELTT) conditioning (p  .03) and use of PBSC
(p  .025). All cases of GVHD were in patients who received
PBSCs. Females with BRCA were 3.3x more likely to develop
GVHD than males with any diagnosis (95% C.I., 1.9-5.8, p 
.0001). Gravidity and parity of females did not statistically affect
the risk for developing GVHD. Since women were more likely to
receive BUMELTT conditioning, the data was analyzed adjusting
for this regimen. A multivariate logistic regression model revealed
the following: (see Table 1)
The hazard of mortality (or relapse) of patients with GVHD
compared to those without was not signiﬁcantly different for the
cohort as a whole nor across different genders/diagnoses (HR:
0.89, 95% C.I. 0.64-1.22, p  .46). Conclusions: Gastrointestinal
GVHD developed in 13% of 681 autologous transplant recipients
and was responsive to short courses of prednisone. Female sex
appears to be the most important risk factor. Although
BUMELTT appears to increase the odds of developing GVHD,
female gender and underlying disease carried an increased risk for
developing GVHD independent of the conditioning regimen.
GRAFT PROCESSING
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SIGNIFICANCE OF LOW PERIPHERAL BLOOD CD34 CELL NUMBERS
PRIOR TO LEUKAPHERESIS: SHOULD THE 5/L THRESHOLD RE-
QUIRED FOR APHERESIS BE CHANGED?
Gidron, A., Doyle, M., Gordon, L., Singhal, S., Tallman, M., Williams,
S., Winter, J., Tomblyn, M., Verma, A., Mehta, J. Northwestern
University, Chicago
The pre-apheresis peripheral blood CD34 cell count
(PBCD34) is a strong predictor of the CD34 cell collection. The
ﬁnal yield is also affected by the blood volume processed and the
CD34 cell collection efﬁciency (CE). It is common practice to
apherese only when PBCD34 is 5/L to avoid poor yields. How-
ever, many patients mobilize stem cells poorly, and the only way to
get enough cells is to collect small numbers at a time over several
days. Omitting apheresis because PBCD34 is below a set value may
prevent them from undergoing a transplant. There are other pit-
falls with this practice: it does not take the patient’s weight into
account, and it ignores the possibility of improving the collection
by processing more blood. Of 485 autologous harvests on Cobe
Spectra over 30 months where PBCD34 was available, 104 were
done with PBCD34 5/L. Volume processed was 15 L (n  57)
or 20 L (n  47). A collection of 0.3  106 CD34 cells/kg was
considered acceptable as this daily yield over a week could add up
to 2  106/kg-enough for an autograft. 60 harvests (58%) had
yields of 0.3; with 49% being 0.4, 38% being 0.5 and 23%
being 0.6. CE for these 104 harvests was 9-145% (median 55%)
compared to 7-132% (median 45%) for the other 381 harvests
performed with PBCD34 5/L (P  0.0001). CE for the 60
harvests with CD34 yields 0.3 was 30-145% (median 70) com-
pared with 9-118% (median 35%) for the 44 with CD34 yields
0.3 (P  0.0001). This suggests that part of the reason for poor
collection was low CE in addition to poor mobilization. The
problem of low CE may be solved in part by using more experi-
enced operators if the mononuclear cell protocol is used for
apheresis or using an automated collection protocol such as
AutoPBSC. These data show that an arbitrary PBCD34 threshold
of 5/L is inappropriate to deny apheresis. We suggest using the
following formula for patients with PBCD34 5/L to decide
about appropriateness of apheresis: 14n/w; where n 
PBCD34/L and w  ideal body weight in kg. A 20 L apheresis
with 70% CE is assumed (20  0.7  14). If 14n/w is 0.3,
apheresis should be performed. This approach is more logical than
using an absolute threshold, and ensures that patients are not
deprived of the opportunity of stem cell collection and autotrans-
plantation. We conclude that it is clinically inappropriate to set an
arbitrary minimum PBCD34 threshold for apheresis. This practice
Table.
Gender/diagnosis O.R. 95% C.I. P Value
Male/lymphoma, myeloma, or hem.
malignancy 1 — —
Female/BRCA 3.4 1.8-6.6 .0002
Female/lymphoma, myeloma, or hem.
malignancy 2.9 1.4-6.0 .003
Male/other diagnoses 3.0 1.2-7.5 .02
Female/other diagnoses 2.2 0.9-5.5 .08
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should be discontinued, and calculations individualized for each
procedure.
25
A NOVEL APPROACH FOR EX-VIVO EXPANSION (EVE) OF NK CD3-/
CD16/56BRIGHT/DIM SUBSETS EXPRESSING INCREASED INHIBITORY
RECEPTORS FROM CRYOPRESERVED/THAWED/EXPANDED/RECRYO-
PRESERVED/RETHAWED (CTECT) AND CRYOPRESERVED/THAWED/RE-
CRYOPRESERVED/RETHAWED/EXPANDED (CTCTE) UMBILICAL CORD
BLOOD (UCB) USING ANTI-CD3, IL-2, IL-7 AND IL-12 (AB/CY)
Ayello, J.1, Satwani, P.1, van de Ven, C.1, Simpson, L.L.1, Kurtzberg,
J.2, Cairo, M.S.1 1. Children’s Hospital of New York-Presbyterian,
Columbia University, New York, NY; 2. Duke University, Durham,
NC
CD56brightdimNK express killer-Ig-like receptors (KIR) and
C-lectin (NKG2), and natural cytoxicity receptors (NCR) involved
with tumor target recognition may play a role in ACI of malig-
nancies (Farag et al, Blood 100:1935, 2002). We compared expan-
sion, maturation and cell survival of CD3-/CD16/56,
CD56bright/dim, KIR inhibitory and C-lectin NK subsets in UCB
aliquots. Non-adherent cells were cultured in SF AIM-V alone or
with anti-CD3 (50 ng/ml), IL-2 (5 ng/ml), IL-7 (10 ng/ml) and
IL-12 (10 ng/ml) (AB/CY). The expanded population was analyzed
for expression of NK subsets (CD94, CD16, CD56bright/dim)
and NK receptors (KIR3DL1, KIR2DL1/S1, KIR2DL2 and
NKG2A) by ﬂow cytometry using CD16, CD56, NKBL1,
CD158a, CD158b, CD94 and NKG2A mAbs. Apoptotic markers
were determined by presence of Annexin V and PI. A signiﬁcant
increase in CD16/CD56bright /dim  and CD94/NKG2A ex-
pression was seen in CTECT and CTCTE in AB/CY compared to
AIM-V alone (CD16/56bright/CTECT: 11 1 vs 2.5 .3%, p
.05; CD16/CD56dim: 46  6 vs 27  2%, p  .03; CD16/
56bright/CTCTE: 9  2 vs 2  .2%, p  .05; CD16/CD56dim:
40  2 vs 27  3%, p  .01; CD94/NKG2A: CTECT: 17  3
vs 2  .9%, p  .001; CTCTE: 25  2 vs 8  3%, p  .001).
Signiﬁcant increases were seen in NK KIR receptors expression
(CD56bright/KIR3DL1 and CD56dim/KIR3DL1) when AB/CY
was compared to AIM-V (CTECT: 11  0.7 vs .4  .07%, p 
.0001; 4  0.1 vs 1.5  0.4%, p  .003; CTCTE: 7  2 vs 1  .3
%, p  .05; 8  1 vs 3  .8%, p  .01, respectively), CD56bright/
KIR2DL1/S1 and CD56dim/KIR2DL1/S1 (CTECT: 12  1 vs
3  .4%, p  .004; 41  2 vs 9  1%, p  .0002; CTCTE: 6 
.5 vs 2  .1%, p  .05; 22  8 vs 5  1, p  .01) and CD56bright/
KIR2DL2 and CD56dim/KIR2DL2 (CTECT: 14  .8 vs 2 
.2%, p  .0002 and 29  .9 vs 12  .4%, p  .0001; CTCTE:
14  2 vs 2  .1%, p  .05 and 25  7 vs 6  1%, p  .001,
respectively). To determine if the increase was secondary to in-
creased cell survival, CTECT and CTCTE AB/CY expanded
cultures showed minimal apoptosis compared to SF AIM-V (1.1 
3 vs 6 .5%, p .001; 5 1 vs 11 .6%, p .05). No signiﬁcant
difference between CTECT and CTCTE modalities was seen
except in CD94/NKG2A (p  .05) and CD56bright/KIR2DL2
(p  .05). These data suggest that CD16/CD56bright/dim NK
subsets expressing increased KIR and C-lectin receptors can be
EvE with AB/CY from CTECT or CTCTE UCB for possible use
in ACI for DLI after UCBT. In-vitro functional and in-vivo
xenotransplant animal studies are underway to further examine the
cytolytic activity of these UCB NK subsets.
26
EX VIVO EXPANSION OF IMMATURE AND MATURE T CELLS DERIVED
FROM UMBILICAL CORD BLOOD (UCB)
Staba, S.L., Crapnell, K.B., Hall, J.G., Reese, M., Kurtzberg, J. Duke
University Medical Center, Durham, NC
Introduction: Unrelated umbilical cord blood (UCB) is an effec-
tive source of allogeneic hematopoietic stem cells for transplanta-
tion therapy in patients lacking matched bone marrow donors.
Opportunistic infection is the major cause of mortality post trans-
plant, due in part to the immunologic naivete´ of the UCB T-cells.
We hypothesized that UCB derived immature and mature T-cells
could be expanded ex-vivo, and utilized a patient-derived skin
stromal layer with a supplemental cytokine cocktail to support the
growth of bulk UCB cells. The long term goal is to provide
UCB-derived adoptive immunotherapy in UCBT recipients.
Methods: Patient derived skin ﬁbroblasts were cultured in a media
of IMDM, 10% fetal calf serum and 10% horse serum for 14 days,
then irradiated to 5,000 cGy. Cryopreserved UCB cells were
thawed and cultured on this stromal layer in the same media
supplemented with a cytokine cocktail of interleukin-7 (IL-7) (10
ng/ml), ﬂt-3 ligand (10 ng/ml), and stem cell factor (50 ng/ml).
UCB cells were cultured with cytokines alone and skin alone as
controls. As a 2nd phase, interleukin-2 (IL-2) was added at day 14
for further expansion, with cells cultured for an additional 14 days
thereafter. Cell count, viability, and FACs analysis were per-
formed. Results: Gating on CD3, in cells cultured with both
skin stroma and cytokines mean fold increases of 6 in CD4, 11 in
CD8 and 34 in CD4/CD8 cells were seen. With cytokines
alone, mean fold increases were 3, 4 and 10 respectively. Minimal
expansion occurred with skin alone. With cytokines and IL-2,
mean fold increases were 4 in CD4, 4 in CD8 and 10 in
CD4/CD8 cells. Maximal expansion occurred with skin
stroma, the cytokine cocktail and IL-2, with mean fold increases of
9 in CD4, 11 in CD8 and 53 in CD4/CD8 cells. Results are
summarized in the table below. Conclusions: The expansion of
T-cells from unfractionated, red blood cell depleted, cryopreserved
UCB can be accomplished using a cytokine cocktail of IL-7, Flt 3
ligand and SCF over a patient derived, irradiated skin stromal
layer. Maximal expansion occurs with the addition of IL-2 and was
greatest in the immature CD4/CD8T-cell subset. We hypoth-
esize that this subset of T cells could serve as a target population
for adoptive immunotherapy, however further testing will deter-
mine the optimal cellular target and conditions for ex vivo expan-
sion and immunization. These cells could then be used to augment
immune reconstitution after UCBT.
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ISOLATION AND FUNCTIONAL INHIBITORY AFFECTS OF SPECIFIC PEP-
TIDES BOUND TO TYPE 2 DENDRITIC CELLS (DC2)
Rosenthal, H.S., Jaye, D.L., Cherry, E., Waller, E.K. Emory Univer-
sity, Atlanta, GA
Introduction: The impact of immunoregulatory type 1 (DC1)
and type 2 (DC2) dendritic cells in allogeneic hematopoetic pro-
genitor cell (HPC) transplantation has increased in interest. We
have shown that greater numbers of DC2s in allogeneic HPC
transplanted grafts has resulted in an increase in post-transplant
relapse and a reduction of graft vs host disease (GVHD). Isolation
of dendritic cell speciﬁc peptides thru phage display technology
provides a method of studying the immunoregulatory affects of
these cells and perhaps engineer grafts with anti-tumor affects.
Method: Random phage peptide libraries were incubated over-
night at 4° C with column enriched peripheral blood DC2 cells.
Unbound phage was removed by washing. FACS sorting of the
Lin-, CD123, HLA-Dr cells, further puriﬁed the DC2 popu-
lation. DC2 bound phage were removed from the cell surface,
eluted and puriﬁed. Three rounds of this phage selection process
(panning) were performed. A portion of the round 2 phage puri-
ﬁcation was incubated with enriched monocytes prior to incuba-
tion with DC2 cells to assist in eliminating phage that recognized
common epitopes on both cell types. Flow cytometry identiﬁed
individual phage clones isolated from plaque assays that were
Table.
Conditions
Mean Fold Expansion
CD4 CD8 CD4/CD8
Skin Alone (n  8) 0 0 0
Cytokines (n  10) 3 4 10
Cytokines  IL-2 (n  5) 4 4 10
Skin  Cytokines (n  10) 6 11 34
Skin  Cytokines  IL-2 (n  5) 9 12 53
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